Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

American Journal of Ophthalmology

Volumn 155, Issue 1, 2013, Pages 96-102.e1

  Yamashita, Ayana ^a   Shiraga, Fumio ^a   Shiragami, Chieko ^a   Shirakata, Yukari ^a   Fujiwara, Atsushi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOCYANINE GREEN; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INTERVENTION STUDY; JAPANESE; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA HEMORRHAGE; VISUAL ACUITY;

EID: 84871216204     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.06.027     Document Type: Article

References (31)

1. Japanese Age-related Macular Degeneration Trial (JAT) Study Group one-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration Am J Ophthalmol 136 6 2003 1049 1061
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1 Arch Ophthalmol 117 10 1999 1329 1345
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2 Arch Ophthalmol 119 2 2001 198 207
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3 Arch Ophthalmol 120 11 2002 1443 1454
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 5 Arch Ophthalmol 120 10 2002 1307 1314
6. Y. Tano Ophthalmic PDT Study Group: Guidelines for PDT in Japan Ophthalmology 115 3 2008 585 585.e6
7. L.A. Yannuzzi, D.W. Wong, and B.S. Sforzolini Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration Arch Ophthalmol 117 11 1999 1503 1510
8. M. Uyama, M. Wada, and Y. Nagai Polypoidal choroidal vasculopathy: natural history Am J Ophthalmol 133 5 2002 639 648
9. K. Sho, K. Takahashi, and H. Yamada Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics Arch Ophthalmol 121 10 2003 1392 1396
10. U. Schmidt-Erfurth, S. Michels, I. Barbazetto, and H. Laqua Photodynamic effects on choroidal neovascularization and physiological choroid Invest Ophthalmol Vis Sci 43 3 2002 830 841
11. U. Schmidt-Erfurth, H. Laqua, U. Schlötzer-Schrehard, A. Viestenz, and G.O. Naumann Histopathological changes following photodynamic therapy in human eyes Arch Ophthalmol 120 6 2002 835 844
12. U. Schmidt-Erfurth, U. Schlötzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G.O. Naumann Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 5 2003 2147 2154
13. The Visudyne in Minimally Classic CNV (VIM) study group Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration Arch Ophthalmol 123 4 2005 448 457
14. S. Michels, F. Hansmann, W. Geitzenauer, and U. Schmidt-Erfurth Influence of treatment parameters on selectivity of verteporfin therapy Invest Ophthalmol Vis Sci 47 1 2006 371 376
15. A. Otani, M. Sasahara, and Y. Yodoi Indocyanine green angiography-guided photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 144 1 2007 7 14
16. F. Gomi, M. Ohji, and K. Sayanagi One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients Ophthalmology 115 1 2008 141 146
17. W.M. Chan, D.S. Lam, and T.Y. Lai Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series Ophthalmology 111 8 2004 1576 1584
18. A. Yamashita, F. Shiraga, C. Shiragami, A. Ono, and K. Tenkumo One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 149 3 2010 465 471
19. E. Akaza, R. Mori, and M. Yuzawa Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy Retina 28 5 2008 717 722
20. Y. Kurashige, A. Otani, and M. Sasahara Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 146 10 2008 513 519
21. Japanese Study Group of Polypoidal Choroidal Vasculopathy Criteria for diagnosis of polypoidal choroidal vasculopathy Nihon Ganka Gakkai Zasshi 109 2005 417 427
22. S. Michels, and U. Schmidt-Erfurth Sequence of early vascular events after photodynamic therapy Invest Ophthalmol Vis Sci 44 5 2003 2147 2154
23. U. Schlötzer-Schrehardt, A. Viestenz, G.O. Naumann, H. Laqua, S. Michels, and U. Schmidt-Erfurth Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes Graefes Arch Clin Exp Ophthalmol 240 9 2002 748 757
24. S. Sacu, A. Varga, and S. Michels Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study Br J Ophthalmol 92 10 2008 1347 1351
25. F. Gomi, M. Sawa, and H. Sakaguchi Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 92 1 2008 70 73
26. A. Tsujikawa, S. Ooto, K. Yamashiro, H. Tamura, A. Otani, and N. Yoshimura Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab Jpn J Ophthalmol 54 4 2010 310 319
27. Y. Mitamura, M. Kitahashi, M. Kubota-Taniai, and S. Yamamoto Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term results Indian J Ophthalmol 58 4 2010 291 296
28. T.Y. Lai, G.K. Lee, F.O. Luk, and D.S. Lam Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy Retina 31 8 2011 1581 1588
29. G.T. Kokame, L. Yeung, and J.C. Lai Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results Br J Ophthalmol 94 3 2010 297 301
30. S. Leal, R. Silva, and J. Figueira Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up Retina 30 8 2010 1197 1205
31. E. Akaza, M. Yuzawa, Y. Matsumoto, S. Kashiwakura, K. Fujita, and R. Mori Role of photodynamic therapy in polypoidal choroidal vasculopathy Jpn J Ophthalmol 51 4 2007 270 277